Compare Stocks

Aztlan Global Stock Selection DM SMID ETF NYSEARCA:AZTD

The Aztlan Global Stock Selection Dm SMID ETF (AZTD) is an exchange-traded fund that mostly invests in extended market equity. The fund tracks an equal-weighted index of 27 mid- and small-cap stocks from developed markets, selected based on six factors: value, cashflow, capital structure, growth, EPS revisions, and price momentum. AZTD was launched on Aug 18, 2022 and is managed by Aztlan.

First Trust Value Line 100 Exchange-Traded Fund NYSEARCA:FVL

First Trust Value Line 100 Exchange-Traded Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Value Line 100 Index (the Index). The Index is an equal-dollar weighted index that is designed to objectively identify and select 100 stocks from the universe of stocks, to which Value Line assigns a #1 ranking in the Value Line Timeliness Ranking System (the Ranking System). At any one time, only 100 stocks are assigned a #1 ranking in the Ranking System. The Index is rebalanced quarterly. The Fund will normally invest at least 90% of its assets in common stocks that comprise the Index. The Fund's investment advisor is First Trust Advisors L.P.

Nightstar Therapeutics NASDAQ:NITE

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.

ELEMENTS Linked to the Morningstar Wide Moat Focus Total Return Index NYSEARCA:WMW